Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

John Strickler; Judith Raimbourg; Jonathan E. Cohen; Francois Ghiringhelli; Manish Sharma; Chiyoe Kitagawa; Ki Hyeong Lee; Bert O'Neil; M. de Miguel; Esma Saada-Bouzid; Rui Li; Nandini Rudra-Ganguly; Adam Luo; A. Parikh; G. Morrison-Thiele; Martha Neagu Aristide; Zoë Hunter; M. Burns; Yasutoshi Kuboki

doi:10.1158/1078-0432.ccr-25-3597

Key Points

To evaluate the antitumor activity and safety profile of Telisotuzumab Adizutecan in advanced gastric and gastroesophageal junction cancer.
First-in-human trial design
Administration of Telisotuzumab Adizutecan as monotherapy
Assessment of safety and activity profile
Temab-A demonstrated notable antitumor activity
The safety profile was manageable
Findings support the potential for combination treatments to enhance outcomes

Implication

First-in-human trial reveals antitumor activity of Temab-A in advanced gastric cancer, suggesting further development is needed.

Abstract

Temab-A monotherapy demonstrated antitumor activity and a manageable safety profile in patients with advanced GEA. The findings support further clinical development of Temab-A, particularly in combination with other agents to improve outcomes for patients with 2L+ GEA.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strickler et al. (2026) studied this question.

synapsesocial.com/papers/69ccb6fd16edfba7beb88d4a https://doi.org/10.1158/1078-0432.ccr-25-3597

View Full Paper

Ask AI

Bookmark

Share

Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met–Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading